Rochester, NY 9/2/2009 9:14:09 PM
ABII Abraxis BioScience, Inc. Results from Phase 2 Study be presented at the 13th Annual World Conference on Lung Cancer
ABII Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Announces results from this phase 2 study show clinical activity that could offer promise in the treatment of this hard to treat cancer. Phase 2 study ABRAXANE in Combination with Carboplatin were presented at the 13th Annual World Conference on Lung Cancer of the International Association for the Study of Lung Cancer (IASLC) in San Francisco, CA.
Last Trade: 26.20
Day's Range: 26.44 - 26.66
Trade Time: 9:58AM ET
52wk Range: 25.82 - 74.50
Change: Down 0.51 (1.91%)
Volume: 11,398
Prev Close: 26.69
Avg Vol (3m): 45,936.4
Open: 26.46
Market Cap: 1.05B
StockEinstein.com offers free trading alerts on stocks about to run. To sign up for our free alert service please click here www.stockeinstein.com or scroll to bottom of this page to sign up.
ABOUT Abraxis BioScience
Abraxis BioScience, Inc., a biotechnology company, engages in the discovery, development, and delivery of next-generation therapeutics and core technologies that offer treatments for cancer and other critical illnesses. The company’s product pipeline includes clinical oncology and cardiovascular product candidates in various stages of testing and development. Its principal product includes Abraxane, a nanoparticle chemotherapeutic compound that is based on its proprietary tumor targeting nab technology platform for the treatment of metastatic breast cancer. Abraxis BioScience's other clinical product candidates include ABI-008, a solvent-free, Tween-free nanometer-sized form of docetaxel for the treatment of hormone refractory prostate cancer and metastatic breast cancer; ABI-009, a nab-rapamycin mTOR inhibitor for the treatment of solid tumors; ABI-010, a polyketide inhibitor of heat shock protein 90 for the treatment of multiple cancers; ABI-011, a thiocolchicine dimer for microtubule destabilization and the disruption of topoisomerase-1 activity; and Coroxane, a nanometer-sized paclitaxel for coronary restenosis and peripheral artery restenosis.
About StockEinstein
StockEinstein.com uses proprietary technologies coupled with years of experience to uncover stocks we feel have the greatest potential for breakout performance. We utilize not only software, but time tested criteria to uncover these potential winners. When these benchmarks are reached or exceeded, our subscribers are immediately notified.
This service is free and available only to subscribers. Scroll down this page or visit our site to join our free newsletter and begin receiving daily stock alerts.
Disclaimer: Full disclaimer at http://StockEinstein.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinstein, nor any of its affiliates are registered investment advisors or broker dealers.
